A Step Forward in Disease Modelling for Mitochondrial Diseases

Overview

Journal Stem Cell Investig

Publisher AME Publishing Company

Date 2017 Dec 23

PMID 29270415

Citations 1

Authors

Filippo Zambelli

Claudia Spits

Affiliations

Soon will be listed here.

Citing Articles

Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?.

McKnight C, Low Y, Elliott D, Thorburn D, Frazier A Int J Mol Sci. 2021; 22(14).

PMID: 34299348 PMC: 8306397. DOI: 10.3390/ijms22147730.

References

Cherry A, Gagne K, McLoughlin E, Baccei A, Gorman B, Hartung O . Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013; 31(7):1287-97. PMC: 3692613. DOI: 10.1002/stem.1354. View

Inak G, Lorenz C, Lisowski P, Zink A, Mlody B, Prigione A . Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease. Stem Cells. 2017; 35(7):1655-1662. DOI: 10.1002/stem.2637. View

Wilkins H, Carl S, Swerdlow R . Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies. Redox Biol. 2014; 2:619-31. PMC: 4297942. DOI: 10.1016/j.redox.2014.03.006. View

Avior Y, Sagi I, Benvenisty N . Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol. 2016; 17(3):170-82. DOI: 10.1038/nrm.2015.27. View

Corti S, Nizzardo M, Simone C, Falcone M, Nardini M, Ronchi D . Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med. 2012; 4(165):165ra162. PMC: 4722730. DOI: 10.1126/scitranslmed.3004108. View

McNeish J, Gardner J, Wainger B, Woolf C, Eggan K . From Dish to Bedside: Lessons Learned While Translating Findings from a Stem Cell Model of Disease to a Clinical Trial. Cell Stem Cell. 2015; 17(1):8-10. DOI: 10.1016/j.stem.2015.06.013. View

Benit P, El-Khoury R, Schiff M, Sainsard-Chanet A, Rustin P . Genetic background influences mitochondrial function: modeling mitochondrial disease for therapeutic development. Trends Mol Med. 2010; 16(5):210-7. DOI: 10.1016/j.molmed.2010.03.001. View

Lorenz C, Lesimple P, Bukowiecki R, Zink A, Inak G, Mlody B . Human iPSC-Derived Neural Progenitors Are an Effective Drug Discovery Model for Neurological mtDNA Disorders. Cell Stem Cell. 2017; 20(5):659-674.e9. DOI: 10.1016/j.stem.2016.12.013. View

Guo X, Disatnik M, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X . Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J Clin Invest. 2013; 123(12):5371-88. PMC: 3859413. DOI: 10.1172/JCI70911. View

10.

Sareen D, Ebert A, Heins B, McGivern J, Ornelas L, Svendsen C . Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One. 2012; 7(6):e39113. PMC: 3378532. DOI: 10.1371/journal.pone.0039113. View

11.

Hatakeyama H, Katayama A, Komaki H, Nishino I, Goto Y . Molecular pathomechanisms and cell-type-specific disease phenotypes of MELAS caused by mutant mitochondrial tRNA(Trp). Acta Neuropathol Commun. 2015; 3:52. PMC: 4546323. DOI: 10.1186/s40478-015-0227-x. View

12.

Kang E, Wang X, Tippner-Hedges R, Ma H, Folmes C, Marti Gutierrez N . Age-Related Accumulation of Somatic Mitochondrial DNA Mutations in Adult-Derived Human iPSCs. Cell Stem Cell. 2016; 18(5):625-36. DOI: 10.1016/j.stem.2016.02.005. View

13.

Kiskinis E, Sandoe J, Williams L, Boulting G, Moccia R, Wainger B . Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014; 14(6):781-95. PMC: 4653065. DOI: 10.1016/j.stem.2014.03.004. View

14.

Kim C . iPSC technology--Powerful hand for disease modeling and therapeutic screen. BMB Rep. 2014; 48(5):256-65. PMC: 4578564. DOI: 10.5483/bmbrep.2015.48.5.100. View

15.

Park I, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A . Disease-specific induced pluripotent stem cells. Cell. 2008; 134(5):877-86. PMC: 2633781. DOI: 10.1016/j.cell.2008.07.041. View